Semaglutide shows promise in reducing cravings for alcohol, heavy drinking, finds study Dr. Kamal Kant Kohli14 Feb 2025 8:15 AM ISTThe blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol...
Semaglutide 2.4 mg Reduces Need for Antihypertensive and Lipid-Lowering Medications in Obesity Treatment: Study Finds Medha Baranwal12 Feb 2025 9:00 AM ISTUSA: A recent analysis of five randomized controlled trials from the STEP program found that adults using semaglutide for obesity were more likely to...
Use of Semaglutide and tirzepatide use linked to ophthalmic complications, finds study Jacinthlyn Sylvia5 Feb 2025 9:00 PM ISTAlmost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in 2023. These medications,...
Semaglutide with Basal Insulin Effective in Diabetes Management: Study Jacinthlyn Sylvia5 Feb 2025 9:00 AM ISTA new systematic review and meta-analysis published in the Clinical Nutrition ESPEN revealed promising outcomes for the combined use of semaglutide...
Sun Pharma Lab gets CDSCO Panel nod to conduct Phase III CT of Semaglutide solution for injection Dr. Divya Colin4 Feb 2025 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug...
Oral Semaglutide Lowers Cravings and Improves Metabolic Health in Type 2 Diabetes Patients: Study Dr Riya Dave1 Feb 2025 9:15 AM ISTA new study published in the journal Diabetes & Vascular Disease Research has found that oral semaglutide reduces total energy intake and changes...
Phase 2b QUALITY Trial: Enobosarm Significantly Reduces Lean Mass Loss in Patients on Semaglutide Dr. Kamal Kant Kohli31 Jan 2025 9:30 AM ISTEnobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with...
FDA approves Semaglutide for renal protection among diabetes patients with CKD Dr. Kamal Kant Kohli30 Jan 2025 9:00 AM ISTNovo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk of worsening kidney...
Novo Nordisk Ozempic get USFDA nod for reduction of kidney disease worsening risk, cardiovascular death in adults with type 2 diabetes, chronic kidney disease Ruchika Sharma29 Jan 2025 1:30 PM ISTPlainsboro: Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease...
Sun Pharma Labs Gets CDSCO Panel Nod Phase-III clinical trial of Semaglutide solution for injection Dr. Divya Colin27 Jan 2025 6:00 PM ISTNew Delhi: Sun Pharma Labs has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
GLP-1 drugs may reduce surgery complications in patients with diabetes, suggests study Dr. Kamal Kant Kohli15 Jan 2025 8:45 AM ISTPeople with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital...
GLP-1 Drugs May Lower Surgical Complications in Diabetes Patients: Study Finds Dr. Bhumika Maikhuri9 Jan 2025 8:15 AM ISTPeople with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital...
